Journal article

Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia

K Dalziel, A Round, R Garside, K Stein

Pharmacoeconomics | ADIS INT LTD | Published : 2005

DOI: 10.2165/00019053-200523050-00010

Citation metrics

33Web of Science
38Scopus

Keywords

Piperazines
Models, Economic
Health Policy & Services
Pharmacology & Pharmacy
Interferon-Alpha
Leukemia, Myelogenous, Chronic, Bcr-Abl Positive
Business & Economics
Hydroxyurea
Chemotherapy
Survival
Pyrimidines
Humans
Science & Technology
Markov Chains
Economics
Cost-Benefit Analysis
Life Sciences & Biomedicine
Benzamides
Health Care Sciences & Services
Imatinib Mesylate
Social Sciences
Antineoplastic Agents